Physician profile
Michael William Graham
NPI 1811429095
$2,184.85
in general payments reported to CMS, 2019-2025
26 companies · $1,561 in 2025
The $1,561 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $624 · 2025: $1,561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,010 · Education: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,009.96 |
| Education | $174.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $553.98 | 2024-2025 | Fasenra, Airsupra, Tezspire |
| Regeneron Healthcare Solutions, INC. | $364.73 | 2024-2025 | Dupixent |
| Pulmonx Corporation | $200.36 | 2024-2025 | Pulmonx Chartis Tablet Console, Chartis Catheter, Zephyr Endobronchial Valve |
| Merck Sharp & Dohme LLC | $120.93 | 2024-2025 | Winrevair, Zerbaxa, Dificid |
| Sanofi-Aventis U.S. LLC | $94.95 | 2024 | |
| Genzyme Corporation | $89.14 | 2024-2025 | |
| Glaxosmithkline, LLC. | $83.29 | 2024-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Galvanize Therapeutics, INC | $67.17 | 2025 | Aliya System |
| Abbvie INC. | $62.14 | 2025 | |
| Axsome Therapeutics, INC. | $61.44 | 2024-2025 | Sunosi |
| United Therapeutics Corporation | $60.55 | 2025 | Tyvaso |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.14 | 2025 | Ofev, Jascayd |
| Amgen INC. | $40.17 | 2025 | Tezspire |
| Viatris Specialty LLC | $38.19 | 2025 | Yupelri |
| Harmony Biosciences LLC | $36.38 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fisher & Paykel Healthcare INC | $35.87 | 2025 | Fisher & Paykel Healthcare |
| Grifols USA, LLC | $34.91 | 2024-2025 | Prolastin-C Liquid |
| Avadel Cns Pharmaceuticals, LLC | $30.65 | 2025 | Lumryz |
| Baxter Healthcare | $24.48 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Genentech USA, INC. | $20.79 | 2024 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $20.13 | 2025 | Glassia |
| Mallinckrodt Hospital Products INC. | $19.05 | 2024 | Acthar |
| Insmed, INC. | $18.01 | 2025 | Brinsupri, Arikayce |
| Inogen, INC. | $17.00 | 2025 | |
| Mylan Specialty L.P. | $16.61 | 2024 | Yupelri |
| Verona Pharma, INC. | $14.79 | 2025 | Ohtuvayre |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Graham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.